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the original work isObjective: Mycobacterium tuberculosis and Cryptococcus neoformans are major
causes of meningitis in HIV-1-infected patients. Identifying differences in the inflam-
matory profiles of HIV-1-associated tuberculous meningitis (TBM) and cryptococcal
meningitis may inform differences in immunopathogenicmechanisms in these diseases.
In this study we compared the clinical and inflammatory features of HIV-1-associated
TBM, and cryptococcal meningitis.
Methods: A prospective study of HIV-1-infected adults who presented with either TBM
[antiretroviral therapy (ART)-naive] or cryptococcal meningitis (regardless of ART
prescription). Clinical and laboratory findings and concentrations of 40 inflammatory
mediators measured in cerebrospinal fluid (CSF, 33 paired with blood) were compared
between TBM and cryptococcal meningitis patients regardless of ART prescription and
between TBM and cryptococcal meningitis patients not receiving ART.
Results: Clinical and laboratory findings were similar in TBM (n¼34) and cryptococcal
meningitis (n¼19; ART prescribed: n¼10, no ART prescribed: n¼9). Exceptions
included a higher median CD4þ cell count [interquartile: 113 (69–199) vs. 25
(8–49) cells/ml, P¼0.0001] and higher HIV-1 median viral load [plasma: 5.46
(4.82–5.89) vs. 4.87 (4.36–5.17) log10copies/ml, P¼0.037; CSF: 6.05 (5.43–6.56)
vs. 5.56 (4.52–5.80) log10copies/ml, P¼0.03] in TBM vs. cryptococcal meningitis
patients not receiving ART. CSF interleukin (IL)-17A was lower in TBM compared with
cryptococcal meningitis [1.00 (0.25–2.35) vs. 9.31 (1.24–23.36) pg/ml,
P-adjusted¼0.03].
Conclusion: Despite presenting with higher peripheral CD4þ cell counts, TBM patients
also presented with higher HIV-1 viral loads compared with cryptococcal meningitis
patients, suggesting a greater propensity of M. tuberculosis compared with C. neofor-
mans to increase HIV-1 replication in vivo. CSF IL-17A was lower in TBM; its role in the
immunopathogenesis of TBM and cryptococcal meningitis deserves further research.
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Mycobacterium tuberculosis and Cryptococcus neoformans are
two major causes of meningitis in HIV-1-infected patients
and contribute substantially to neurological disease burdens
in high HIV-1 prevalence settings [1–5]. Recent treatment
trials report high mortality rates for HIV-1-associated
cryptococcal meningitis (30–50%) [6,7] and tuberculous
meningitis (TBM, 58%) [8]. Several studies have compared
clinical and cerebrospinal fluid (CSF) findings in patients
with cryptococcal meningitis and TBM: both present
subacutely (days to weeks after neurological symptom
onset) and CSF findings of high protein, low glucose and
lymphocytosis, are frequently indistinguishable in these
groups [5,9–13].
The immunopathogenesis of cryptococcal meningitis and
TBM remains unclear. Studies investigating correlates of
human immunity to cryptococcal infection have reported
associations between high pretreatment CSF interleukin
(IL)-6, interferon (IFN)-g, tumor necrosis factor (TNF) and
IL-8 concentrations and 2-week survival in patients with
HIV-1-associated cryptococcal meningitis [14,15]. In
patients with HIV-1-associated TBM, one study found an
independent association between lower CSF IFN-g (but not
other cytokines such as TNF, IL-6 or IL-8) at presentation
and death [16]. Others report correlations between higher
IFN-g andTNFanddisease severity inHIV-1-infected and -
uninfected TBM patients combined [17].
Studies that compare inflammatory mediators in patients
with cryptococcal meningitis and TBM, which may
inform differences in immunopathogenic mechanisms in
these diseases, are limited. Patel et al. compared CSF IFN-
g and C-X-C chemokine ligand (CXCL)10 between
patients with TBM and controls with other causes of
meningitis, 58% (28/48) of whom had cryptococcal
meningitis [18]. Other studies investigated inflammatory
markers simultaneously in cryptococcal meningitis and
TBM, such as TNF [19,20], IFN-g [20], TGF-b1 [20],
matrix metalloproteinases (MMP)-2 and -9 [20–22] and
tissue inhibitors of MMP (TIMP)-1 and -2 [22].
However, these studies did not present statistical
comparisons between findings in TBM and cryptococcal
meningitis [18–22] or included a limited number (n< 4)
in either of these patient groups [19,22]. In this study we
report the clinical and laboratory findings, including an
analysis of a wide range of inflammatory mediators in
patients with HIV-1-associated TBM compared with
HIV-1-associated cryptococcal meningitis.Methods
Setting and participants
A prospective, observational study at a public sector
hospital in Cape Town, South Africa from March 2009 toJanuary 2011. We enrolled antiretroviral therapy (ART)-
naive HIV-1-infected adults ( 18 years) who presented
with TBM diagnosed according to a published case
definition [23]. As control participants we enrolled HIV-
1-infected adults with cryptococcal meningitis, regardless
of ART prescription, diagnosed by a positive CSF India
ink stain and/or cryptococcal antigen latex agglutination
test (CLAT); central nervous system (CNS) infection
with C. neoformans was subsequently confirmed by a
positive CSF culture. We further compared findings
between cryptococcal meningitis patients and a control
group of ART-naive HIV-1-infected patients who did not
have meningitis (referred to as the ‘no-meningitis’
group). The details of comparisons of findings between
the TBM group and the no-meningitis group [24], as well
as comparisons of findings in TBM patients who did and
did not developed TBM-immune reconstitution inflam-
matory syndrome (IRIS), have previously been described
[24,25]. The University of Cape Town Human Research
Ethics Committee approved the study (HREC 232/
2008) and written informed consent was obtained from
all patients or their relatives.
Procedures
Demographic data, history of TB and cryptococcal
disease, and HIV-1 infection were recorded and a
neurological examination performed. Paired CSF and
blood samples were then collected. Blood investigations
included full blood count, electrolytes and renal function,
C-reactive protein, CD4þ cell count and HIV-1 viral
load. CSF analysis included biochemistry, microbiology
(microscopy and culture for fungi, pyogenic bacteria and
M. tuberculosis), syphilis serology and CLAT. CSF HIV-1
viral load was performed in TBM patients and
cryptococcal meningitis patients not receiving ART.
Aliquots of CSF and blood were stored at 80 8C and
analyzed for inflammatory mediators as detailed below. At
diagnosis, TBM patients commenced TB treatment
(prescribed for a total duration of 9 months) and
prednisone (starting dose: 1.5 mg/kg per day, weaned
over 6 weeks). Patients with cryptococcal meningitis
commenced amphotericin B (0.7 mg/kg per day for
2 weeks), followed by daily oral fluconazole (400 mg for
8 weeks then 200 mg until CD4þ cell count >200 cells/
ml for more than 6 months on ART). TBM patients were
followed up for the duration of TB treatment, whilst
cryptococcal meningitis patients and no-meningitis
controls were seen once only (at presentation). We
subsequently used the South African National Health
Laboratories Service database and the electronic hospital
register to trace cryptococcal meningitis patients to
determine their in-hospital and 9-month outcome.
Luminex multiplex and enzyme-linked
immunosorbent assay performed on blood and
cerebrospinal fluid samples
As previously described for TBM patients and no-
meningitis controls [24], mediators analyzed in CSF and
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IFN-a2, IL-1b, IL-2, IL-4, IL-6, IL-10, IL-12p40, IL-
13, IL-17, C-C chemokine 2 ligand (CCL2), CCL3,
CCL4, CXCL1–3, CXCL8, granulocyte colony-stimu-
lating factor (G-CSF) and granulocyte-macrophage
(GM)-CSF. MMP-1, -2, -3, -7, -9, -10, -12 and -13,
and TIMP-1 and -2 were analyzed by Luminex multiplex
in CSF and plasma. Mediators measured by enzyme-
linked immunosorbent assay (ELISA) in CSF and serum
samples included IL-12p70, IL-17A, IL-21, IL-22, IL-23
and CXCL10. CSF was also analyzed by ELISA for IL-18
and neutrophil-associated mediators: cathepsin G, lipo-
calin-2, LL-37, human neutrophil peptides (HNP) 1–3,
complement (C) 5a and S100A8/A9.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
version 5 (GraphPad Software, Inc., San Diego,
California, USA) and R version 3.0 [26]. Findings were
compared between patients with TBM and all crypto-
coccal meningitis (CM) patients (i.e. including patients
who were receiving ART at the time of presentation and
those who were not, referred to as the ‘combined-CM’
group). As none of the TBM patients were receiving
ART at presentation, subgroup analyses were also
performed for TBM patients and cryptococcal meningitis
patients who were not receiving ART at time of
cryptococcal meningitis presentation (including ART-
naive patients and patients who defaulted ART, referred
to as the ‘CM-off-ART’ group). Findings were further
compared between CM-off-ART patients and crypto-
coccal meningitis patients receiving ART at presentation
(referred to as the ‘CM-on-ART’ group), and between
cryptococcal meningitis patients (combined-CM and
CM-off-ART groups) and no-meningitis controls.
Between groups, categorical variables were compared
using Fischer’s exact test and continuous variables were
compared using Wilcoxon rank-sum tests. Continuous
variables between blood and CSF compartments, within
groups, were compared using Wilcoxon matched-pairs
tests. P-values were adjusted for a false discovery rate
(FDR, Benjamini-Hochberg) for analyses of inflamma-
tory mediators; an adjusted P-value (P-adj)< 0.05 was
considered to be statistically significant [27]. Correlations
were estimated using Spearman’s rho.Results
Demographic and clinical results
Thirty-four TBM patients and 19 cryptococcal menin-
gitis patients, including 10 of 19 (53%) who had received
ART for a median of 31 days (IQR, 18–87) at the time of
presentation, were included in this study. The demo-
graphic and baseline findings for TBM, combined-CM
and CM-off-ART groups are presented in Table 1, and
comparisons of findings between CM-on-ARTand CM-off-ART patients are presented in Table S1, Supplemental
Digital Content (SDC) 1, http://links.lww.com/QAD/
A791. Six CM-off-ART patients were ART-naive
whereas three had defaulted ART 2, 6 and 19 months
prior to cryptococcal meningitis presentation, respect-
ively. Three cryptococcal meningitis patients presented
with a recurrence of cryptococcal meningitis; one
developed CM-IRIS 4, and 2, months after initial
cryptococcal meningitis diagnosis and ART initiation,
respectively, whilst two were not receiving ART at the
time of cryptococcal meningitis presentation. Prior TB
was common in both groups; 11 (32%) TBM and 9 (47%)
cryptococcal meningitis patients had a history of previous
successfully treated pulmonary TB (P¼ 0.38) and five
cryptococcal meningitis patients were receiving treat-
ment for pulmonary TB (duration, range: 3–10 months)
at cryptococcal meningitis presentation; all five crypto-
coccal meningitis patients on TB treatment had shown an
appropriate symptomatic response to TB treatment.
Neurological symptoms and examination findings were
similar between the TBM and cryptococcal meningitis
groups. Baseline characteristics and routine investigation
findings of 14 ART-naive HIV-1-infected controls
without meningitis, compared with findings in crypto-
coccal meningitis and TBM patients, are presented in
Table S2, SDC1, http://links.lww.com/QAD/A791.
Blood and cerebrospinal fluid findings
Blood and CSF findings (Table 1) were similar between
TBM and cryptococcal meningitis patients with the
following exceptions: CSF lymphocyte counts were
higher in TBM patients compared with combined-CM
patients [177 (87–339) vs. 90 (7–132) cells/ml,
P¼ 0.031; Fig. 1h]. TBM patients had higher blood
CD4þ cell counts compared with combined-CM patients
[median (IQR), 113 (69–199) vs. 55 (23–77) cells/ml,
P¼ 0.0012]. This difference between TBM and crypto-
coccal meningitis was more pronounced when analyzing
only CM-off-ART patients [CD4þ: 25 (8–49) cells/ml,
P¼ 0.0001]. TBM patients also presented with higher
HIV-1 viral loads, both in plasma [5.46 (4.82–5.89) vs.
4.87 (4.36–5.17) log10 copies/ml, P¼ 0.037] and in CSF
[6.05 (5.43–6.56) vs. 5.56 (4.52–5.80) log10 copies/ml,
P¼ 0.031] compared with CM-off-ART patients. As
migratory leukocytes may contribute to CSF HIV viral
load, we assessed correlation between CSF HIV viral
loads and total CSF leukocyte counts (lymphocytes and
neutrophils) and between CSF HIV viral loads and CSF
lymphocyte counts, in TBM and CM-off-ART patients
(Table S3, SDC1, http://links.lww.com/QAD/A791).
No significant correlations were observed in either group
in any of these analyses.
As previously described for the TBM group [24] and
shown in Table S2, SDC1, http://links.lww.com/QAD/
A791, combined-CM patients had lower sodium [128
(126–132) vs. 135 (133–137) mmol/l, P¼ 0.0009] and
higher C-reactive protein [23 (6–66) vs. 5 (1–8) mg/l,
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Fig. 1. Cerebrospinal fluid Luminex multiplex/ELISA showing results for inflammatory mediators and cells different by
univariate analysis in tuberculous meningitis (TBM) and cryptococcal meningitis (CM). Results for TBM, combined-CM and
CM-off-antiretroviral therapy (ART) groups are shown. Horizontal lines within graphs represent median concentrations. Statistical
analysis between TBM and CM groups displayed as unadjusted/adjusted P-values on horizontal bars: N/S P0.05,
0.05<P0.01. 0.01<P 0.001. 0.001<P 0.0001. P-values were adjusted for a false discovery rate (Benjamini-
Hochberg) for analysis of inflammatory mediators.P¼ 0.02] concentrations compared with no-meningitis
patients. Both CD4þ cell counts and HIV viral loads
were lower in combined-CM patients compared with
controls [CD4þ: 55 (23–77) vs. 129 (75–180) cells/ml,
P¼ 0.0042; HIV viral load: 3.93 (2.18–4.93) vs. 4.87
(4.44–5.44) log10 copies/ml, P¼ 0.029]. CM-off-ART
patients had lower CD4þ cell counts (P¼ 0.0013), but
comparable HIV viral loads (P¼ 0.76) compared with
no-meningitis patients. Similar to patients with TBM
[24], cryptococcal meningitis patients had higher CSF
lymphocyte counts, neutrophil counts and protein
concentrations, and lower CSF : blood glucose ratios,
compared with the no-meningitis group (P< 0.01
for all).Management and outcome
In addition to amphotericin B, TB treatment was started
in three cryptococcal meningitis patients for suspected
pulmonary TB. In none of these patients was a diagnosis
of TB confirmed microbiologically; TB treatment was
started empirically based on chest radiograph findings that
could have been consistent with either TB or crypto-
coccosis in two patients, and in the third, chest radiograph
findings showed fibrotic changes (the patient had previous
TB) and active disease could not be excluded. None of
the no-meningitis patients commenced TB treatment.
None of the TBM patients but three cryptococcal
meningitis patients died during hospitalization and
9-months mortality was 12% (n¼ 4) and 37% (n¼ 7)
400 AIDS 2016, Vol 30 No 3(P¼ 0.41) for TBM and combined-CM patients,
respectively with no loss-to-follow-up.
Inflammatory mediators measured by enzyme-
linked immunosorbent assay or Luminex
multiplex
IL-12p70 and IL-23 were undetectable in any blood or
CSF sample. These mediators were therefore excluded
from further analysis.
Table 2 shows univariate analyses of CSF and blood
inflammatory mediator findings comparing TBM and
combined-CM patients; comparisons of results between
TBM and CM-off-ART are presented in Table S4,
SDC1, http://links.lww.com/QAD/A791. As we
described previously for TBM [24], cryptococcal
meningitis patients presented with a compartmentalized
inflammatory response with higher CSF concentrations
of G-CSF, IFN-a2, TNF, IL-6, IL-17A, CCL2, CCL3,
CXCL8, CXCL10, MMP-9 and TIMP-1
(P-adj0.0001); IFN-g, IL-10, CCL4 (0.001<P-
adj<0.01); and IL-13 (0.01<P-adj<0.05), compared
with blood in the combined-CM group (Table 2).
Conversely, CXCL1–3 (P-adj¼ 0.0075) and MMP-1, -
2, -3, -7 and -10 (P-adj0.0045) were higher in blood
compared with CSF in these patients.
When comparing CSF findings in TBM to those in
combined-CM patients, TBM patients had higher IFN-g
(P¼ 0.018), IL-1b (0.0027), CXCL10 (P¼ 0.01),
MMP-1 (P¼ 0.011) and MMP-3 (P¼ 0.0099), and
lower IL-17A (P¼ 0.0007) and MMP-10 (P¼ 0.02) by
univariate analysis (Table 2, Fig. 1). However, only IL-
17A remained significantly different between these
groups (P-adj¼ 0.03) after adjustment for FDR. Similar
trends in differences were seen when comparing IL-1b,
IL-17A, MMP-1 and MMP-10 between TBM and CM-
off-ART groups (Table S4, SDC1, http://links.lww.-
com/QAD/A791 and Fig. 1); none of these remained
significantly different after adjustment for FDR. Table S5,
SDC1, http://links.lww.com/QAD/A791 shows Spear-
man’s rho and P-values for correlations between CSF IL-
17A concentrations and the following: blood HIV viral
loads, CSF HIV viral loads and blood CD4þ cell counts,
in TBM and cryptococcal meningitis groups. Notably, no
significant correlation was observed in either group in any
of the analyses performed.
Concentrations of mediators measured in blood were
similar in TBM and cryptococcal meningitis patients,
with the exception of CXCL10 and IFN-g that were
higher, and CCL2 and CCL4 that were lower
(0.01<P< 0.05 for all) in TBM patients compared with
combined-CM patients (Table 2). CCL2 and CXCL10
were similarly different when TBM was compared
with CM-off-ART (0.01<P< 0.05 for both; Table S4,
SDC1, http://links.lww.com/QAD/A791). None ofthese differences remained significant after adjustment
for FDR.
CSF and blood concentrations of mediators were similar
between cryptococcal meningitis patients irrespective of
ART (Table S6, SDC1, http://links.lww.com/QAD/
A791) with only two significant differences between
these groups in univariate analysis: higher plasma MMP-
10 [median (IQR): 1018 (608–1372) vs. 527 (159–578)
pg/ml, P¼ 0.031] and lower CSF TIMP-1 [242297
(154658–417305) vs. 477480 (287021–794524) pg/ml,
P¼ 0.040] in CM-off-ART patients; neither of these
differences were significant after adjustment for FDR.
As was previously described for TBM patients [24] (Table
S7, SDC1, http://links.lww.com/QAD/A791), com-
bined-CM patients had significantly higher concen-
trations of most mediators measured in CSF compared
with no-meningitis patients, both when comparing
combined-CM and CM-off-ART groups to these
controls (Tables S8 and Table S9, SDC1, http://
links.lww.com/QAD/A791). The only mediators that
were not significantly higher in combined-CM patients
compared with no-meningitis controls after adjustment
for FDR were MMP-3 that were similar, and IL-1b, IL-
2, IL-4, IL-21, IL-22, MMP-12, MMP-13, IL-18 and
C5a that had medians equal to zero, in both groups (Table
S8, SDC1, http://links.lww.com/QAD/A791). Similar
differences were seen when comparing CM-off-ART
patients to no-meningitis controls (Table S9, SDC1,
http://links.lww.com/QAD/A791). There were no
significant differences between mediators measured in
blood after adjustment for FDR between both com-
bined-CM and CM-off-ART groups and no-meningitis
controls (Tables S8 and S9, SDC1, http://links.lww.com/
QAD/A791).Discussion
As previously reported in studies comparing HIV-1-
associated cryptococcal meningitis and TBM [5,10], the
clinical and basic laboratory features in these groups were
similar; notable exceptions that were also found in a study
of ART-naive meningitis patients from a high TB/HIV-1
prevalence setting [12] were higher CD4þ cell counts and
higher CSF lymphocyte counts in TBM patients. Despite
presenting with higher peripheral CD4þ cell counts,
TBM patients also presented with higher HIV-1 viral
loads, both in blood and CSF, compared with crypto-
coccal meningitis patients not receiving ART. Leucocytes
that have migrated from peripheral blood into the CNS
could potentially increase the CSF HIV viral load and in
this study, TBM patients had higher CSF lymphocyte
counts compared with cryptococcal meningitis patients.
However, we did not find any correlation between
leukocyte counts and HIV viral loads in either TBM or
Interleukin-17 in HIV-associated meningitides Marais et al. 401
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402 AIDS 2016, Vol 30 No 3CM-off-ART patients. Both M. tuberculosis [28] and C.
neoformans [29] accelerate HIV-1 replication in vitro, and
findings from bronchoalveolar lavage fluid suggest a
similar effect of M. tuberculosis on HIV-1 replication in the
lungs of pulmonary TB patients [30]. Based on our
findings, we hypothesize that of the two pathogens, M.
tuberculosis more significantly stimulates HIV-1 replication
in vivo in the periphery as well as at the site-of-disease,
potentially resulting in increased HIV-1-associated CNS
pathology in TBM compared with cryptococcal menin-
gitis patients.
Our results reveal a pathologically important difference in
IL-17A concentrations at the site-of-disease in patients
with TBM and cryptococcal meningitis. CSF IL-17A was
significantly higher in combined-CM compared with
TBM patients in univariate analysis after adjustment for
FDR. It is unlikely that this difference was related to the
higher peripheral blood CD4þ cell counts and HIV viral
loads (in both blood and CSF) observed in the TBM
group compared with patients with cryptococcal
meningitis, as no significant correlation was observed
between the concentrations of IL-17A and any of these
factors in either TBM or cryptococcal meningitis
patients. As previously reported [24], we have also not
found any significant correlation between the concen-
trations of the mediators measured in CSF and CSF
leucocyte counts in TBM patients. Through the
induction of neutrophil recruitment, IL-17 promotes
inflammatory pathology in autoimmune disease but
protects the host against many pathogens [31,32]. In a
murine model of cryptococcal lung disease, IL-17A
promoted host defense against C. neoformans by increasing
leukocyte recruitment, IFN-g production and activation
of lung myeloid cells [33]. In patients with HIV-1-
associated cryptococcal meningitis not on ART, increased
concentrations of CSF IL-17A in combination with
increased concentrations of other cytokines (IL-10 and
classical Th1 cytokines) was associated with a IFN-g/
TNF-a producing cryptococcal antigen-specific periph-
eral blood T cells response that, in turn, associated with
lower 2-week mortality [34]. A protective role for IL-17
against TB infection has also been inferred from studies in
mice [32]. However, IL-17 may potentially be detri-
mental in TB as over-expression of IL-17 through
induction of S100A8/A9 mediated neutrophil recruit-
ment and exacerbated lung inflammation in TB-infected
mice [35]. A harmful role for IL-17 in TBM was also
suggested by CSF findings in TBM-IRIS, a potentially
life-threatening complication of ART in TB patients
characterized by severe CNS inflammation [24]; IL-17A
concentrations increased significantly after starting TB
treatment in TBM-IRIS patients. Given these findings, it
is intriguing to consider that the inflammatory response
associated with IL-17 may play different and possibly
opposite roles in the immunopathogenesis of TBM and
cryptococcal meningitis, being harmful in the former and
protective in the latter.In both TBM and cryptococcal meningitis patients the
inflammatory response was highly compartmentalized in
the CSF, with concentrations of the majority of cytokines
and chemokines measured being significantly higher in
CSF compared with blood. This is consistent with
previous reports of other forms of extrapulmonary TB
[36,37] and cryptococcal meningitis [38]. Furthermore,
we found no significant differences in mediators
measured in blood of TBM compared with cryptococcal
meningitis patients. These findings emphasize the
importance of investigating mediators at the site-of-
disease (i.e. CSF), rather than solely relying on blood
samples, when investigating immunopathogenic mech-
anisms in TBM and cryptococcal meningitis.
Although this is the most extensive comparison of
inflammatory mediators in HIV-1-associated TBM vs.
cryptococcal meningitis, we acknowledge several limita-
tions. We were unable to include a control group of HIV-
uninfected patients without TB and cryptococcal
meningitis as such patients are less common in our high
HIV/TB setting. Due to the relatively small sample size,
some biologically relevant differences between groups
may have passed undetected by univariate analysis. We
also made conservative choices (using less powerful
nonparametric tests) as even log transformed mediators
had nonnormal distributions, typical for this type of data.
Given further the large number of mediators analyzed and
the large interindividual differences in mediator concen-
trations, straightforward multivariate analysis was not
suitable for this dataset. In particular, logistic regression
relies on relatively large sample sizes for good approxi-
mation of parameter estimates and is not suitable in this
case. Our findings should therefore be considered
preliminary, requiring validation in larger studies.
In conclusion, we demonstrated potentially important
immunological differences between TBM and crypto-
coccal meningitis in spite of similar clinical characteristics.
A propensity for M. tuberculosis to increase HIV
replication compared with C. neoformans may have
important implications for the control of HIV infection
in co-infected patients. Furthermore, IL17 may play
different roles in the pathogenesis of TBM and
cryptococcal meningitis. We anticipate that our findings
will guide future studies to investigate different patho-
genic mechanisms that may ultimately inform host-
directed treatment strategies in HIV-1-associated TBM
and cryptococcal meningitis.Acknowledgements
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